Ramiro Ribeiro Sells 42,544 Shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $17.10, for a total transaction of $727,502.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eyepoint Pharmaceuticals Trading Up 3.0%

Shares of NASDAQ:EYPT traded up $0.51 during trading on Wednesday, reaching $17.37. The stock had a trading volume of 1,205,300 shares, compared to its average volume of 1,012,825. The firm’s 50-day simple moving average is $15.14 and its 200 day simple moving average is $12.86. Eyepoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $19.11. The company has a market capitalization of $1.44 billion, a P/E ratio of -5.81 and a beta of 1.63.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. The firm had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $3.33 million. Equities research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on EYPT shares. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Mizuho set a $28.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Royal Bank Of Canada boosted their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $29.25.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors have recently bought and sold shares of EYPT. Corient Private Wealth LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $1,200,000. Dynamic Technology Lab Private Ltd lifted its holdings in Eyepoint Pharmaceuticals by 127.8% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 73,310 shares of the company’s stock valued at $397,000 after purchasing an additional 41,132 shares in the last quarter. Walleye Capital LLC boosted its stake in Eyepoint Pharmaceuticals by 500.6% during the 2nd quarter. Walleye Capital LLC now owns 199,449 shares of the company’s stock worth $1,877,000 after purchasing an additional 166,243 shares during the last quarter. XTX Topco Ltd boosted its stake in Eyepoint Pharmaceuticals by 215.4% during the 2nd quarter. XTX Topco Ltd now owns 137,950 shares of the company’s stock worth $1,298,000 after purchasing an additional 94,210 shares during the last quarter. Finally, Stempoint Capital LP purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth $3,098,000. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.